Online citations, reference lists, and bibliographies.
← Back to Search

Toward Consistency In Cost-utility Analyses: Using National Measures To Create Condition-specific Values.

M. Gold, P. Franks, K. I. McCoy, D. Fryback
Published 1998 · Psychology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
OBJECTIVES The authors developed an "off-the-shelf" source of health-related quality of life (HRQL) scores for cost-effectiveness analysts unable to collect primary data. METHODS The authors derived and conducted preliminary validation on a set of health-related quality of life scores for chronic conditions using nationally representative data from the National Health Interview Survey (NHIS) and the Healthy People 2000 Years of Healthy Life measure developed to monitor the health (longevity and health-related quality of life) of Americans during this decade. The measure comprises two domains, role function and self-rated health, and is scaled from 0 (death) to 1 (best health state). Health-related quality of life scores for chronic conditions were calculated using the Years of Healthy Life scores associated with chronic conditions reported in the 1987-1992 National Health Interview Survey. Preliminary validation was examined by comparing the health-related quality of life scores with those obtained in two other studies. RESULTS Tables provide health-related quality of life scores for persons with and without conditions. The scores had reasonable face validity, ranging from 0.87 for allergic rhinitis to 0.27 for hemiplegia. Correlations of the health-related quality of life condition weight scores with those from two other studies were 0.78 and 0.86. CONCLUSIONS These condition weights may prove useful to investigators conducting cost-effectiveness analyses using secondary data, where community ratings of health-related quality of life for chronic conditions are required. Use of a standard set of health-related quality of life weights gathered from a national sample can enhance the comparability of cost-effectiveness analyses. Improvements in national data collection techniques, with empirical gathering of preferences, will further strengthen this measure.
This paper references
Health status: types of validity and the index of well-being.
R. Kaplan (1976)
10.1287/OPRE.30.6.1043
Application of Multi-Attribute Utility Theory to Measure Social Preferences for Health States
G. Torrance (1982)
10.1016/S0095-5108(18)30920-5
Cost-effectiveness of antepartum prevention of Rh immunization.
G. Torrance (1984)
A general health policy model: update and applications.
R. Kaplan (1988)
10.1001/JAMA.1988.03720160029025
The cost-effectiveness of cervical cancer screening for low-income elderly women.
J. Mandelblatt (1988)
10.1016/0895-4356(88)90076-5
Patient-proxy response comparability on measures of patient health and functional status.
J. Magaziner (1988)
10.1093/OXFORDJOURNALS.AJE.A115418
Issues in carrying out epidemiologic research in the elderly.
J. Kelsey (1989)
10.1016/0895-4356(89)90136-4
Methodology for measuring health-state preferences--II: Scaling methods.
D. Froberg (1989)
EuroQol : a new facility for the measurement of health-related quality of life
A. Williams (1990)
10.1111/j.1749-6632.1990.tb30324.x
Cost‐Effectiveness of Hormone Replacement
M. Weinstein (1990)
10.1097/00005650-199109000-00004
Multitrait-Multimethod Analysis of Health-Related Quality-of-Life Measures
D. Hadorn (1991)
10.1001/ARCHINTE.1991.00400050062012
Prioritization of health care services. A progress report by the Oregon Health Services Commission.
H. Klevit (1991)
10.1097/00005650-199102000-00004
The Validity of Proxy-Generated Scores as Measures of Patient Health Status
M. Rothman (1991)
10.7326/0003-4819-116-3-238
Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly?
I. Udvarhelyi (1992)
10.1016/0895-4356(92)90083-Y
Improving task comprehension in the measurement of health state preferences. A trial of informational cartoon figures and a paired-comparison task.
D. Hadorn (1992)
10.1097/00005650-199307001-00001
Health Care CBA/CEA: An Update on the Growth and Composition of the Literature
A. Elixhauser (1993)
10.1177/0272989X9301300202
The Beaver Dam Health Outcomes study
D. Fryback (1993)
10.1093/OXFORDJOURNALS.AJE.A117078
Comparing self-reported and physician-reported medical history.
R. Kehoe (1994)
10.1001/JAMA.273.15.1185
Variation in patient utilities for outcomes of the management of chronic stable angina. Implications for clinical practice guidelines. Ischemic Heart Disease Patient Outcomes Research Team.
R. F. Nease (1995)
10.1056/NEJM199505253322106
Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
D. Mark (1995)
10.7326/0003-4819-123-1-199507010-00011
Economic Analysis of Health Care Technology: A Report on Principles
A. Hillman (1995)
10.1001/JAMA.1995.03520390045031
Variation in Patient Utilities for Outcomes of the Management of Chronic Stable Angina: Implications for Clinical Practice Guidelines
R. Nease (1995)
10.1016/0895-4356(94)00186-T
Large-scale health outcomes evaluation: how should quality of life be measured? Part II--Questionnaire validation in a cohort of patients with advanced cancer.
D. Hadorn (1995)
10.1001/JAMA.1996.03540140060028
The Role of Cost-effectiveness Analysis in Health and Medicine
L. Russell (1996)
10.1001/JAMA.276.14.1172
The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine.
L. Russell (1996)
10.1097/00005650-199602000-00008
Assessing the health of the nation. The predictive validity of a preference-based measure and self-rated health.
M. Gold (1996)
10.1177/0272989X9701700303
Dollars May Not Buy as Many QALYs as We Think:
D. Fryback (1997)



This paper is referenced by
10.1016/j.amepre.2021.01.023
Higher-Valency Pneumococcal Conjugate Vaccines: An Exploratory Cost-Effectiveness Analysis in U.S. Seniors.
Kenneth J Smith (2021)
10.1371/journal.pcbi.1008470
The value of decreasing the duration of the infectious period of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
Bruce Y. Lee (2021)
10.1016/j.vaccine.2021.03.040
Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore.
L. C. Phua (2021)
10.1371/journal.pmed.1003534
Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis
Jane J. Kim (2021)
10.3390/vaccines9020111
Inclusion of Safety-Related Issues in Economic Evaluations for Seasonal Influenza Vaccines: A Systematic Review
T. Fens (2021)
10.1016/j.jpurol.2021.01.024
Utility estimation for neurogenic bowel dysfunction in the general population.
Kirsten L Simmons (2021)
10.1101/2020.05.29.20117184
How Efficacious Must a COVID-19 Coronavirus Vaccine be to Prevent or Stop an Epidemic by Itself
S. Bartsch (2020)
10.1016/j.amepre.2019.10.022
Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. Populations.
Angela R Wateska (2020)
10.1097/GOX.0000000000002986
Cost-effectiveness Analysis of Abdominal-based Autogenous Tissue and Tissue-expander Implant following Mastectomy
A. Thoma (2020)
10.1080/20477724.2020.1857492
Impact of COVID-19 infection control measures on influenza-related outcomes in Hong Kong
J. H. You (2020)
10.1097/GOX.0000000000003179
Comparing the Clinical and Cost-Effectiveness of Abdominal-based Autogenous Tissue and Tissue-Expander Implant: A Feasibility Study
A. Thoma (2020)
10.1016/j.canep.2020.101861
Health economic evaluation of primary human papillomavirus screening in urban populations in China.
Adam Keane (2020)
10.1001/jamanetworkopen.2020.12522
Evaluation of the Cost-effectiveness of Infection Control Strategies to Reduce Hospital-Onset Clostridioides difficile Infection
A. Barker (2020)
10.1016/j.vaccine.2020.10.019
Cost-effectiveness of HPV vaccination for adults through age 45 years in the United States: Estimates from a simplified transmission model.
H. Chesson (2020)
10.1111/jgs.16373
Cost‐Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older Populations
Angela R Wateska (2020)
10.1136/ijgc-2018-000161
Clinical impact and cost-effectiveness of primary cytology versus human papillomavirus testing for cervical cancer screening in England
Irenjeet Bains (2019)
10.1186/s12879-019-4108-y
Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK
S. Datta (2019)
10.1016/j.ajic.2019.05.003
Standing orders program of pneumococcal vaccination for hospitalized elderly patients in Hong Kong: A cost-effectiveness analysis.
Nianli Xing (2019)
10.1111/jce.14153
Potential cost‐effectiveness of wearable cardioverter‐defibrillator for patients with implantable cardioverter‐defibrillator explant in a high‐income city of China
X. Jiang (2019)
10.1002/sim.8157
Prioritized concordance index for hierarchical survival outcomes.
L. Cheung (2019)
10.1016/j.ijid.2018.10.007
Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China.
Qianqian Fan (2019)
10.1245/s10434-019-07160-x
A Systematic Review of Utility Score Assessments in the Breast Surgery Cost-Analysis Literature
Alexander Y. Yoon (2019)
10.1101/19012674
Impact and cost-effectiveness of nonavalent human papillomavirus vaccination in Switzerland: insights from a dynamic transmission model
M. Riesen (2019)
10.1007/s10900-019-00716-8
Cost-Effectiveness of Pneumococcal Vaccination and Uptake Improvement Programs in Underserved and General Population Adults Aged < 65 Years
Angela R Wateska (2019)
10.1016/j.vaccine.2019.01.002
Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50-64 years compared to the US general population.
Angela R Wateska (2019)
10.1080/21645515.2018.1564439
An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysis
Angela R Wateska (2019)
10.1001/jamacardio.2018.4566
Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events
T. Sehested (2019)
10.1007/s10620-019-05821-1
Fecal Transplants by Colonoscopy and Capsules Are Cost-Effective Strategies for Treating Recurrent Clostridioides difficile Infection
Yuying Luo (2019)
10.1186/s12879-018-2967-2
Cost-effectiveness of increasing vaccination in high-risk adults aged 18–64 Years: a model-based decision analysis
Angela R Wateska (2018)
10.1007/s10620-018-5141-1
Cost-Effectiveness of Melanoma Screening in Inflammatory Bowel Disease
A. Anderson (2018)
10.22034/APJCP.2018.19.4.933
Comparative Cost-Effectiveness Analysis of Two Different Two-Dose Human Papillomavirus Vaccines in Malaysia
G. V. Kriekinge (2018)
10.1016/j.bjid.2017.11.004
Cost-utility of quadrivalent versus trivalent influenza vaccine in Brazil - comparison of outcomes from different static model types.
L. Van Bellinghen (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar